Maria Valencia

UGenome would love to meet you in San Diego from June 1-5! #ugenome, #ugenomeai, #pharmacogenomics, #pharmacogenetics, #bioinformatics, #genetics, #dna, #research, #genomics, #medicine, #drugdiscovery, #datascience, #biostatistics, #pharma, #genomicmedicine, #sequencing, #dataanalysis, #precisionmedicine

3

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

Innovative trial designs and advanced imaging modalities could address the challenges of early drug development, ultimately improving outcomes for patients with solid tumors. In an Applied Clinical Trials Magazine article, our VP of Oncology, Ravi Karra, discusses how we can overcome challenges in early phase drug development for solid tumors. Read now: https://hubs.la/Q02x0zBt0 #Oncology #SolidTumors #ClinicalTrials #DrugDevelopment

46

5 Comments

Innovative trial designs and advanced imaging modalities could address the challenges of early drug development, ultimately improving outcomes for patients with solid tumors. In an Applied Clinical Trials Magazine article, our VP of Oncology, Ravi Karra, discusses how we can overcome challenges in early phase drug development for solid tumors. Read now: https://hubs.la/Q02yj05h0 #Oncology #SolidTumors #ClinicalTrials #DrugDevelopment

21

1 Comment

Join our upcoming webinar next week with California Life Sciences (CLS), featuring Avance Clinical’s scientific and regulatory affairs experts, showcasing the clinical trials landscape and regulatory frameworks that are essential for accelerating drug development programs towards global approval. Our experts Alex Kavros, PhD, Kevin Leach, Ph.D, DABT and Jorgen Mould will delve into the intricacies of the drug development process, offering deep dives into the critical phases of bringing a therapeutic concept to the clinic. From the foundational steps in preclinical research to the pivotal milestones of Phase I and II clinical trials, attendees will gain invaluable insights. Register here: https://bit.ly/49VgOiB #AvanceClinical #CLS #CaliforniaLifeSciences #earlystagebiotech #drugdevelopment #Australia #UnitedStates #CRO #scientificaffairs #regulatoryaffairs #webinar #experts #preclinical #clinicaltrials

34

📢 Entos Pharmaceuticals Opens State-of-the-Art GMP Facility 📢 Entos Pharmaceuticals has opened a GMP facility in Carlsbad, CA to support IND-enabling studies and clinical trials. 🔬 The facility is 20,000 square feet and will help Entos advance its pipeline of 20 programs. 💰 The cost of the facility has not been disclosed, but it has room for expansion. 🌎 Entos also plans to build a commercial manufacturing facility in Alberta, Canada, as part of its global manufacturing strategy. #BioprocessUpdates #EntosPharmaceuticals #GMPfacility #manufacturing #clinicaltrials #INDenablingstudies #pharmaceuticalindustry #CarlsbadCA #pipeline #expansion #globalmanufacturing #AlbertaCanada #commercialmanufacturing #biotech #pharmaceuticals #medicalresearch ▷ Read the full article here: 📎 https://lnkd.in/dE4eRN7n

36

Vaidehi Joshi, Director, Discovery Biology at Viscient Bio Inc, graced our 20th BioPharma Drug Discovery event in San Diego, CA with her enlightening presentation on "Three-Dimensional primary cell based liver model predicts clinical outcomes of MASH in vitro" Gain invaluable insights into the future of liver disease research and clinical outcomes prediction!" #BioPharmaNexus #Discovery #invitro #Biology #Procurementdirect #NexusConference #SanDiego #Cell #ClinicalOutcomes #Scientific #USAconference #Disease #NexusConference

129

2 Comments

Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC The FDA on Thursday greenlit the use of Genentech’s Alecensa (alectinib) for the adjuvant treatment of patients with early-stage, anaplastic lymphoma kinase-positive non-small cell lung cancer who have undergone tumor resection. With the approval, Alecensa is now the “first and only” ALK inhibitor approved for this indication and patient population, according to Genentech. Thursday’s regulatory win is backed by data from the Phase III ALINA trial, a randomized, active-controlled and open-label study comparing adjuvant Alecensa with platinum-based chemotherapy. The study enrolled 257 patients with Stage IB to IIIA tumors who had undergone resection and tested positive for anaplastic lymphoma kinase (ALK) using an FDA-approved test. Results from ALINA, which the company released in October 2023, showed that Alecensa could cut the risk of disease recurrence or death by 76% versus platinum-based chemotherapy. This treatment effect was highly significant and yielded a p-value of less than 0.0001. The ALK blocker also led to a significant improvement in central nervous system-disease-free survival, according to an exploratory analysis of ALINA. Genentech CMO Levi Garraway in a statement on Thursday called ALINA’s disease-free survival data “unprecedented,” adding that “Alecensa significantly improves upon the standard of care for people with early-stage ALK-positive lung cancer.”

88

1 Comment

Ambry is at #ACOG2024! Come see us at Booth #1400. We look forward to speaking to you about our hereditary cancer testing offerings, complete with +RNAinsight™, and demonstrating how Ambry is setting the standard in #genetictesting. #breastcancer #GYNcancer

39

Mark Tornetta, VP of Biologics Discovery at Tavotek Biotherapeutics discussed "Fully synthetic nanobody libraries and how to manage the diversity they produce into late-stage pre-clinical" at #DDSS. This insightful presentation took place on #Day1 of #DDSS2024! Keep an eye out for further updates from #15thddss2024. #PharmaInnovation #UnlockPotential #summit2024 #staytunedformore."

26

Did you know today is #NationalDNADay? At Vigil, we honor today by celebrating the advances of genomic research & its impact on our lives. Understanding your genome is crucial for us all, especially those at risk for genetic diseases.   If you have a family history of #ALSP, learn about ALSPAware, a no-cost, confidential genetic counseling and testing program: informeddna.com/alspaware/ #VigilantForYou 

33

Thoughts on this? >> Takeda budgets $230M for plasma therapy facility expansion in California >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

1

"Precisely targeted therapies for patients with cancer." Nuvalent, Inc. specializes in developing targeted therapies for cancer patients using innovative small molecules to inhibit kinase targets. Their approach focuses on overcoming resistance and ensuring selectivity in treatments. Learn more: https://nuvalent.com/ #CancerTherapy #PharmaceuticalInnovation #SoHCSpotlights

1